• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Variations in Echogenicity in Carotid and Femoral Atherosclerotic Plaques with Pycnogenol + Centella Asiatica Supplementation.补充碧萝芷+积雪草后颈动脉和股动脉粥样硬化斑块回声性的变化
Int J Angiol. 2017 Jun;26(2):95-101. doi: 10.1055/s-0036-1594292. Epub 2016 Dec 26.
2
Carotid plaque stabilization induced by the supplement association Pycnogenol® and centella asiatica (Centellicum®).碧萝芷®与积雪草(Centellicum®)联合补充剂诱导的颈动脉斑块稳定化。
Minerva Cardioangiol. 2016 Dec;64(6):603-9. Epub 2015 Oct 23.
3
Pycnogenol® and Centella asiatica to prevent asymptomatic atherosclerosis progression in clinical events.碧萝芷®和积雪草可预防临床事件中无症状动脉粥样硬化的进展。
Minerva Cardioangiol. 2017 Feb;65(1):24-31. doi: 10.23736/S0026-4725.16.04008-1. Epub 2015 Oct 27.
4
Pycnogenol® and Centella asiatica in the management of asymptomatic atherosclerosis progression.碧萝芷®与积雪草用于无症状动脉粥样硬化进展的管理
Int Angiol. 2015 Apr;34(2):150-7. Epub 2014 Dec 18.
5
Central cardiovascular calcifications: supplementation with Pycnogenol® and Centellicum®: variations over 12 months.中心性心血管钙化:补充碧萝芷®和积雪草®:12个月内的变化情况
Minerva Cardioangiol. 2020 Feb;68(1):22-26. doi: 10.23736/S0026-4725.19.05052-7. Epub 2019 Oct 15.
6
Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®.无症状动脉粥样硬化斑块患者动脉粥样硬化进展和心血管事件的延迟:补充碧萝芷®+积雪草提取物三年的预防作用
Minerva Cardioangiol. 2020 Feb;68(1):15-21. doi: 10.23736/S0026-4725.19.05051-5. Epub 2019 Oct 11.
7
Keloidal penile fibrosis: improvements with Centellicum® (Centella asiatica) and Pycnogenol® supplementation: a pilot registry.瘢痕性阴茎纤维化:使用 Centellicum®(积雪草)和 Pycnogenol®补充剂的改善:初步注册研究。
Panminerva Med. 2020 Mar;62(1):13-18. doi: 10.23736/S0031-0808.18.03572-3.
8
Pycnogenol® and Centella Asiatica for asymptomatic atherosclerosis progression.碧萝芷®与积雪草用于无症状动脉粥样硬化进展情况
Int Angiol. 2014 Feb;33(1):20-6.
9
Pycnogenol®+Centellicum®, post-stent evaluation: prevention of neointima and plaque re-growth.碧萝芷®+积雪草,支架置入后评估:预防新生内膜和斑块再生长。
Minerva Cardioangiol. 2019 Dec;67(6):450-455. doi: 10.23736/S0026-4725.19.05048-5.
10
Pycnogenol®-Centellicum® supplementation improves lung fibrosis and post-COVID-19 lung healing.碧萝芷®-积雪草提取物补充剂可改善肺纤维化和新冠后肺脏的修复。
Minerva Med. 2022 Feb;113(1):135-140. doi: 10.23736/S0026-4806.20.07225-0. Epub 2021 Jun 28.

本文引用的文献

1
Pycnogenol® and Centella asiatica to prevent asymptomatic atherosclerosis progression in clinical events.碧萝芷®和积雪草可预防临床事件中无症状动脉粥样硬化的进展。
Minerva Cardioangiol. 2017 Feb;65(1):24-31. doi: 10.23736/S0026-4725.16.04008-1. Epub 2015 Oct 27.
2
Pycnogenol® and Centella asiatica in the management of asymptomatic atherosclerosis progression.碧萝芷®与积雪草用于无症状动脉粥样硬化进展的管理
Int Angiol. 2015 Apr;34(2):150-7. Epub 2014 Dec 18.
3
Effects of Pycnogenol® on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study.碧萝芷®对临界高血压、高脂血症和高血糖个体内皮功能障碍的影响:临界研究
Int Angiol. 2015 Feb;34(1):43-52. Epub 2014 Nov 13.
4
The Carotid intima-media thickness modification following atorvastatin is bound to the modification of the oxidative balance.阿托伐他汀治疗后颈动脉内膜中层厚度的改变与氧化平衡的改变相关。
J Cardiovasc Pharmacol Ther. 2014 Sep;19(5):446-50. doi: 10.1177/1074248414528574. Epub 2014 Apr 17.
5
Pycnogenol® and Centella Asiatica for asymptomatic atherosclerosis progression.碧萝芷®与积雪草用于无症状动脉粥样硬化进展情况
Int Angiol. 2014 Feb;33(1):20-6.
6
Safety of statins.他汀类药物的安全性。
Indian J Endocrinol Metab. 2013 Jul;17(4):636-46. doi: 10.4103/2230-8210.113754.
7
OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.OATP1B1 相关的药物-药物和药物-基因相互作用是导致西立伐他汀引起横纹肌溶解的潜在危险因素。
Pharmacogenet Genomics. 2013 Jul;23(7):355-64. doi: 10.1097/FPC.0b013e3283620c3b.
8
Atherosclerosis: current status of prevention and treatment.动脉粥样硬化:预防与治疗的现状
Int J Angiol. 2011 Dec;20(4):213-22. doi: 10.1055/s-0031-1295520.
9
Evidence-based management of carotid artery disease.基于证据的颈动脉疾病管理
Int J Angiol. 2010 Spring;19(1):e21-4. doi: 10.1055/s-0031-1278367.
10
Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study.碧萝芷对稳定性冠心病患者血管内皮功能的影响:一项双盲、随机、安慰剂对照、交叉研究。
Eur Heart J. 2012 Jul;33(13):1589-97. doi: 10.1093/eurheartj/ehr482. Epub 2012 Jan 11.

补充碧萝芷+积雪草后颈动脉和股动脉粥样硬化斑块回声性的变化

Variations in Echogenicity in Carotid and Femoral Atherosclerotic Plaques with Pycnogenol + Centella Asiatica Supplementation.

作者信息

Belcaro Gianni, Cornelli Umberto

机构信息

Irvine Labs, Chieti-Pescara University, Spoltore, Pescara, Italy.

出版信息

Int J Angiol. 2017 Jun;26(2):95-101. doi: 10.1055/s-0036-1594292. Epub 2016 Dec 26.

DOI:10.1055/s-0036-1594292
PMID:28566935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5446256/
Abstract

This registry study evaluated echogenicity of carotid-femoral plaques in asymptomatic subjects with increased oxidative stress and risk factors (mild hypertension, hypercholesterolemia). Supplementation with the combination Pycnogenol-CA (centella asiatica) on the echogenicity of plaques was assessed at 6 months (79 subjects). A standard management (SM) plan was used in all subjects (control of risk factors, lifestyle changes); 36 subjects used the supplements +SM; 43 SM only. The groups were comparable. High-resolution ultrasound evaluated echogenicity and plaque structure. Pycnogenol (150 mg/day) and CA (Centellicum, 450 mg/day) were used. At 6 months, cholesterol was reduced ( < 0.05) in both groups (difference between groups not significant). At 6 months, plasma free radicals were decreased with the supplements (17.64%;  < 0.05; vs <2% in controls). The plaque stability index increased from 11.22;2.3 to 22.4;1.1 ( < 0.05) with the supplements; no significant changes were seen in controls. Plaque echogenicity (% of "whiter" component in images) increased with supplementation from 16.7;1.7% to 34.2;2% ( < 0.05); no variations were observed in controls. The maximum plaque height decreased ( < 0.05) with the supplements. No significant variations were observed in controls. Plaque length was decreased ( < 0.05) in the supplement group with no changes in controls. The number of plaques (carotid, femoral bifurcations) decreased with supplementation; no significant changes were observed in controls. No adverse events, tolerability problems, or variations in routine blood tests were recorded. The combination Pycnogenol-CA appears to improve echogenicity and stability of complex plaques in 6 months.

摘要

这项注册研究评估了氧化应激增加且伴有风险因素(轻度高血压、高胆固醇血症)的无症状受试者颈动脉 - 股动脉斑块的回声性。在6个月时评估了补充碧萝芷 - 积雪草(积雪草)组合对斑块回声性的影响(79名受试者)。所有受试者均采用标准管理(SM)方案(控制风险因素、改变生活方式);36名受试者使用补充剂 + SM;43名仅采用SM。两组具有可比性。采用高分辨率超声评估回声性和斑块结构。使用了碧萝芷(150毫克/天)和积雪草(积雪草属,450毫克/天)。6个月时,两组的胆固醇均有所降低(<0.05)(两组间差异不显著)。6个月时,补充剂组的血浆自由基减少(17.64%;<0.05;对照组减少<2%)。补充剂组的斑块稳定性指数从11.22;2.3增至22.4;1.1(<0.05);对照组未见显著变化。补充剂组斑块回声性(图像中“更白”成分的百分比)从16.7;1.7%增至34.2;2%(<0.05);对照组未见变化。补充剂组斑块最大高度降低(<0.05)。对照组未见显著变化。补充剂组斑块长度降低(<0.05),对照组无变化。补充剂组斑块数量(颈动脉、股动脉分叉处)减少;对照组未见显著变化。未记录到不良事件、耐受性问题或常规血液检查的变化。碧萝芷 - 积雪草组合似乎在6个月内改善了复杂斑块的回声性和稳定性。